{"&cites=1882792696390332365&as_sdt=2005&sciodt=0,5&hl=en":[{"title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a …","url":"https://www.sciencedirect.com/science/article/pii/S1470204519304139","authors":["RJ Motzer","RJ Motzer BI Rini","RJ Motzer BI Rini DF McDermott","RJ Motzer BI Rini DF McDermott OA Frontera…"],"year":2019,"numCitations":99,"pdf":"https://researchers.mq.edu.au/en/publications/nivolumab-plus-ipilimumab-versus-sunitinib-in-first-line-treatmen","citationUrl":"http://scholar.google.com/scholar?cites=6021365036904200257&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:QbihN5kvkFMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=6021365036904200257&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier","p":1,"exp":1596876833628},{"title":"Life Science","url":"http://www.forskasverige.se/wp-content/uploads/life-science1.pdf","authors":["AFM ANNONS"],"year":1960,"numCitations":401,"pdf":"http://www.forskasverige.se/wp-content/uploads/life-science1.pdf","citationUrl":"http://scholar.google.com/scholar?cites=12960782180278116341&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:9Z-wSrny3bMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=12960782180278116341&hl=en&as_sdt=2005&sciodt=0,5","publication":"forskasverige.se"},{"title":"Updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic …","url":"https://www.sciencedirect.com/science/article/pii/S0302283819304269","authors":["L Albiges","L Albiges T Powles","L Albiges T Powles M Staehler","L Albiges T Powles M Staehler K Bensalah","L Albiges T Powles M Staehler K Bensalah RH Giles…"],"year":2019,"numCitations":48,"pdf":"https://www.researchgate.net/profile/Thomas_Lam5/publication/333671322_Updated_European_Association_of_Urology_Guidelines_on_Renal_Cell_Carcinoma_Immune_Checkpoint_Inhibition_Is_the_New_Backbone_in_First-line_Treatment_of_Metastatic_Clear-cell_Renal_Cell_Carcinoma/links/5cfd92d392851c874c5b4fc7/Updated-European-Association-of-Urology-Guidelines-on-Renal-Cell-Carcinoma-Immune-Checkpoint-Inhibition-Is-the-New-Backbone-in-First-line-Treatment-of-Metastatic-Clear-cell-Renal-Cell-Carcinoma.pdf","citationUrl":"http://scholar.google.com/scholar?cites=1736679606747912938&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:6trfqObsGRgJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1736679606747912938&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Immune checkpoint inhibitors of PD-L1 as cancer therapeutics","url":"https://link.springer.com/article/10.1186/s13045-019-0779-5","authors":["A Akinleye","A Akinleye Z Rasool"],"year":2019,"numCitations":43,"pdf":"https://link.springer.com/article/10.1186/s13045-019-0779-5","citationUrl":"http://scholar.google.com/scholar?cites=14221940144688408840&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:CCkF5TV7XsUJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14221940144688408840&hl=en&as_sdt=2005&sciodt=0,5","publication":"Springer"},{"title":"Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy","url":"https://link.springer.com/article/10.1186/s13045-019-0718-5","authors":["S Qin","S Qin A Li","S Qin A Li M Yi","S Qin A Li M Yi S Yu","S Qin A Li M Yi S Yu M Zhang","S Qin A Li M Yi S Yu M Zhang K Wu"],"year":2019,"numCitations":30,"pdf":"https://link.springer.com/article/10.1186/s13045-019-0718-5","citationUrl":"http://scholar.google.com/scholar?cites=15224292450592355156&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:VPM3clKNR9MJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=15224292450592355156&hl=en&as_sdt=2005&sciodt=0,5","publication":"Springer"},{"title":"Towards individualized therapy for metastatic renal cell carcinoma","url":"https://www.nature.com/articles/s41571-019-0209-1","authors":["RR Kotecha","RR Kotecha RJ Motzer","RR Kotecha RJ Motzer MH Voss"],"year":2019,"numCitations":26,"citationUrl":"http://scholar.google.com/scholar?cites=14400902405870945540&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:BIUBW3BI2scJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14400902405870945540&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"},{"title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas …","url":"https://www.sciencedirect.com/science/article/pii/S1470204519304589","authors":["RS Herbst","RS Herbst HT Arkenau","RS Herbst HT Arkenau R Santana"],"year":2019,"numCitations":27,"citationUrl":"http://scholar.google.com/scholar?cites=1017422728817139702&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:9t-N0ZScHg4J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1017422728817139702&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Next-generation computational tools for interrogating cancer immunity","url":"https://www.nature.com/articles/s41576-019-0166-7","authors":["F Finotello","F Finotello D Rieder","F Finotello D Rieder H Hackl","F Finotello D Rieder H Hackl Z Trajanoski"],"year":2019,"numCitations":25,"citationUrl":"http://scholar.google.com/scholar?cites=8524515517286431371&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:i7opurIpTXYJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=8524515517286431371&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"},{"title":"The intersection between tumor angiogenesis and immune suppression","url":"https://clincancerres.aacrjournals.org/content/25/18/5449.abstract","authors":["OE Rahma","OE Rahma FS Hodi"],"year":2019,"numCitations":22,"citationUrl":"http://scholar.google.com/scholar?cites=6140166113107344266&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:inunQYxANlUJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=6140166113107344266&hl=en&as_sdt=2005&sciodt=0,5","publication":"AACR"},{"title":"Combination therapy as first-line treatment in metastatic renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMe1900887","authors":["B Escudier"],"year":2019,"numCitations":19,"citationUrl":"http://scholar.google.com/scholar?cites=969670948256617057&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:YRLaA5f2dA0J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=969670948256617057&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"}]}